Company Active LTD

Company profile

Applied Photophysics Limited

Applied Photophysics

Applied Photophysics are specialists in Circular Dichroism and Stopped-Flow Spectrometry, providing solutions for the Biophysical Characterization of Biomolecules worldwide.

CRN
01006739
Founded
1971
Age
55

Overview

Legal name
APPLIED PHOTOPHYSICS LIMITED
Region
South East England
Registered address
21 MOLE BUSINESS PARK
LEATHERHEAD
SURREY
KT22 7BA
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

1 level 1 ultimate controller Controls 2
1
Company Active LTD
Applied Photophysics Limited
CRN 01006739
2
Direct and ultimate controller Active LTD
Apl Holdings Limited
CRN 02493532

Company events

Reference milestones and recent Companies House filing stream events.

6 events
16 Dec
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Mar
2026

Accounts due

Accounts Due

Next accounts due date

02 Dec
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

20 Sep
2024

Accounts With Accounts Type Small

Accounts Awaiting analysis

AA | Transaction MzQzNjQxMTM0NmFkaXF6a2N4

Published 20 Sep 2024 05:05

30 Jun
2024

Accounts filed

Accounts

Last accounts made up date

01 Apr
1971

Incorporated

Inception

Company registered at Companies House

Public funding

6 awards
First funded
2013
Funded years
2013, 2016, 2018, 2019, 2020, 2021
Age at first award
42 years

Projects

2021 Collaborative R&D Lead participant

Industry ready Higher Order Structure analysis system for Biopharma

8 Jan 2021 to 8 Jan 2023

Awarded
£697,628
Total cost £697,628

This project is a follow on project to: "Practical Applications of circular dichroism spectroscopy for biopharmaceuticals." Reference number 102611 which finished in October 2017. Higher Order Structure (HOS) of a biopharmaceutical is a key quality attribute required to be controlled throughout the development and manufacture of a biologic drug or vaccine...

2020 Feasibility Studies Lead participant

High throughput protein stability analysis systems for biopharma

1 Jun 2020 to 31 Mar 2021

Awarded
£250,000
Total cost £262,390

no public description

2019 Innovation Loans Lead participant

High throughput protein stability analysis systems for biopharma

14 Jun 2019 to 14 Jul 2021

Awarded
£1,000,000
Total cost £1,107,631

High throughput protein stability analysis systems for biopharma

2018 Feasibility Studies Lead participant

Automated high throughput protein stability measurement system

1 Jul 2018 to 31 Dec 2018

Awarded
£38,138
Total cost £54,482

"To ensure product safety and efficacy, protein therapeutic critical quality attributes must remained within tolerances for the duration of the shelf life of the product, as well as during transportation, storage and use. Consequently development of and testing for long term stability of the protein drug product is a major focus of biotherapeutic developm...

2016 Collaborative R&D

Practical application of Circular Dichroism for biopharmaceuticals

1 Nov 2016 to 31 Oct 2017

Awarded
£104,976
Total cost £149,966

Circular dichroism (CD) spectroscopy is an analytical technique routinely used in the biopharmaceutical industry to study the effects of manufacturing, formulation, and storage conditions on protein conformation and stability. The difficulty in data interpretation of CD is limited to demonstrating conformational comparability after a manufacturing/formula...

2016 Collaborative R&D Lead participant

Biopharmaceutical HOS analysis by automated fast hydrogen deuterium exchange

1 Sep 2016 to 31 May 2019

Awarded
£368,423
Total cost £526,318

Knowledge of a biopharmaceutical product’s higher order structure (HOS) and conformational dynamics, and how these relate to it’s mode of action and/or degradation, are central to enable effective and streamlined biopharmaceutical development through QbD-based approaches. Hydrogen deuterium exchange mass spectrometry (HDX MS) is a technique increasingly u...

2013 GRD Development of Prototype Lead participant

Comparison of the higher-order structure of biosimilar and innovator biotherapeutic drugs using automated circular dichroism: a novel approach to validation, measurement and analysis by Applied Photophysics Limited

1 Jun 2013 to 28 Feb 2015

Awarded
£250,000
Total cost £732,424

Eight of the predicted top-ten drugs by revenue in 2016 will be biotherapeutics and as early as 2014, 50% of the top-100 pharmaceutical products will be accounted for by vaccines and biotherapeutics. Understandably, pharmaceutical companies are competing to establish new biotherapeutic drug pipelines, both as innovator and generic manufacturers. The socie...

Product types

Collaborative R&D Feasibility Studies GRD Development of Prototype Innovation Loans